News
RIGL
35.61
-0.34%
-0.12
Weekly Report: what happened at RIGL last week (0615-0619)?
Weekly Report · 1d ago
A Look At The Transformation Around Rigel Pharmaceuticals
Seeking Alpha · 3d ago
As U.S. profit margins near record highs, these small-cap stocks lead on profitability
Seeking Alpha · 5d ago
Rigel Expands Oncology Portfolio with VEPPANU Global Rights
TipRanks · 6d ago
Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU
PUBT · 6d ago
These small-cap healthcare stocks pair revenue growth with attractive valuations
Seeking Alpha · 6d ago
Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal
Seeking Alpha · 6d ago
Rigel Pharmaceuticals publishes corporate presentation outlining commercial growth strategy and pipeline priorities
PUBT · 06/16 20:25
Rigel closes license agreement for Veppanu
TipRanks · 06/16 20:13
Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement
Benzinga · 06/16 20:04
RIGEL ANNOUNCES CLOSING OF LICENSING AGREEMENT FOR VEPPANU™ (VEPDEGESTRANT)
Reuters · 06/16 20:01
Weekly Report: what happened at RIGL last week (0608-0612)?
Weekly Report · 06/15 10:28
Weekly Report: what happened at RIGL last week (0601-0605)?
Weekly Report · 06/08 10:23
Pantginis Reiterates Buy on Rigel, Citing Strengthening Oncology Portfolio and Unchanged $57 Price Target
TipRanks · 06/02 11:17
Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
Dow Jones · 06/02 11:12
These 10 small-cap U.S. healthcare giants rank among the market's most attractively valued stocks
Seeking Alpha · 06/01 14:20
Weekly Report: what happened at RIGL last week (0525-0529)?
Weekly Report · 06/01 10:28
Rigel Pharma director Kamil Ali-Jackson disposes of 2,500 common shares worth $72,925
PUBT · 05/28 20:20
Knight Therapeutics launches Tavalisse in Mexico for chronic immune thrombocytopenia
PUBT · 05/27 23:02
Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
Dow Jones · 05/27 15:12
More
Webull provides a variety of real-time RIGL stock news. You can receive the latest news about Rigel Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.